title: Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
abstract: BACKGROUND
  Staging of Hodgkin's disease (HD) is accomplished by a variety of invasive and non-invasive modalities. This prospective study was undertaken to investigate the value of whole-body positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) in defining regions involved by lymphoma compared with conventional staging methods in patients with HD.
  
  
  METHODS
  Fourty-four newly diagnosed patients with HD underwent FDG-PET as part of their initial staging work-up. PET findings were correlated with findings of conventional staging including computed tomography, ultrasound, bone scanning, bone marrow biopsy, liver biopsy and laparotomy. When results of FDG-PET differed to those obtained by conventional methods reevaluation was performed by biopsy, if possible, or magnetic resonance imaging.
  
  
  RESULTS
  The results of FDG-PET were compared with three hundred twenty-one conventional staging procedures performed in 44 patients. FDG-PET was positive in 38 of 44 (86%) patients at sites of documented disease. PET detected additional lesions in five cases previously not identified by conventional staging methods. In another case a nodal lesion suspect on CT was negative at FDG-PET and was settled as true negative by biopsy. As a consequence of PET findings five patients had to be upstaged and one patient had to be downstaged, resulting in changes in treatment strategy in all six cases (14%). FDG-PET failed to visualize sites of HD in four patients. In two of our patients a false positive PET result was obtained.
  
  
  CONCLUSIONS
  Our data indicate that FDG-PET provides an imaging technique that appears to visualize involved lesions in most patients with HD and is useful in the management of these patients.
authors.affiliation: Department of Medicine III (Hematology, Oncology, Clinical Immunology and Infectious Diseases), University of Ulm, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Bangerter
authors.forename: F
authors.initials: F
authors.lastname: Moog
authors.forename: I
authors.initials: I
authors.lastname: Buchmann
authors.forename: J
authors.initials: J
authors.lastname: Kotzerke
authors.forename: M
authors.initials: M
authors.lastname: Griesshammer
authors.forename: M
authors.initials: M
authors.lastname: Hafner
authors.forename: K
authors.initials: K
authors.lastname: Elsner
authors.forename: N
authors.initials: N
authors.lastname: Frickhofen
authors.forename: S N
authors.initials: SN
authors.lastname: Reske
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18